GILEAD SCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
GILEAD SCIENCES, INC. (GILD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 4.40% for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-23.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2022-02-23
- GILEAD SCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 4.40%, a 10.00% increase from fiscal 2020.
- GILEAD SCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2020 was 4.00%, a 11.11% increase from fiscal 2019.
- GILEAD SCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2019 was 3.60%, a 28.57% increase from fiscal 2018.
- GILEAD SCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2018 was 2.80%, a 3.70% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|
| 2021-12-31 | 4.40% 10-K · filed 2022-02-23 |
| 2020-12-31 | 4.00% 10-K · filed 2022-02-23 |
| 2019-12-31 | 3.60% 10-K · filed 2022-02-23 |
| 2018-12-31 | 2.80% 10-K · filed 2021-02-25 |
| 2017-12-31 | 2.70% 10-K · filed 2020-02-25 |
| 2016-12-31 | 1.90% 10-K · filed 2019-02-26 |
| 2015-12-31 | 1.70% 10-K · filed 2018-02-27 |
| 2014-12-31 | 0.00% 10-K · filed 2017-02-27 |
| 2013-12-31 | 0.00% 10-K · filed 2016-02-24 |
| 2012-12-31 | 0.00% 10-K · filed 2015-02-25 |
| 2011-12-31 | 0.00% 10-K · filed 2014-02-25 |
| 2010-12-31 | 0.00% 10-K · filed 2013-02-27 |
| 2009-12-31 | 0.00% 10-K · filed 2012-02-23 |
| 2008-12-31 | 0.00% 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |